SCHEMBL5887963

SCHEMBL5887963

COC(C)OCOc1ccc(/C=C/c2ccc(C(=O)O)cc2)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 10/20 0.60
IKBKB O14920 6/20 0.60
RARB P10826 7/20 0.57
RARG P13631 7/20 0.57
MEN1 O00255 1/20 0.46
NR1I2 O75469 1/20 0.46
LMNA P02545 1/20 0.46
PGR P06401 1/20 0.46
HSPD1 P10809 1/20 0.46
GOT1 P17174 1/20 0.46
GLRA1 P23415 1/20 0.46
BLM P54132 1/20 0.46
HSPE1 P61604 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HDAC11 Q96DB2 4/20 0.45
HDAC2 Q92769 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887970 1.00 RARA (0.60) RARAIKBKBRARBRARGMEN1
SCHEMBL8433871 0.93 RARA (0.54) RARAIKBKBRARBRARGMEN1
SCHEMBL8433862 0.93 RARA (0.54) RARAIKBKBRARBRARGMEN1
SCHEMBL8426163 0.91 RARA (0.74) RARAIKBKBRARBRARGMEN1
SCHEMBL5887896 0.89 RARA (0.49) RARAIKBKBRARBRARGMEN1
SCHEMBL5887891 0.89 RARA (0.49) RARAIKBKBRARBRARGMEN1
SCHEMBL5888166 0.89 RARA (0.55) RARAIKBKBRARBRARGMEN1
SCHEMBL5887955 0.88 RARA (0.71) RARAIKBKBRARBRARGMEN1
SCHEMBL5887940 0.88 RARA (0.71) RARAIKBKBRARBRARGMEN1
SCHEMBL5887932 0.88 RARA (0.71) RARAIKBKBRARBRARGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6992095-B2 Stilbene compounds comprising an adamantyl group, compositions and methods thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US claimed
US-20040067971-A1 Stilbene compounds comprising an adamantyl group, compositions and methods thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-04-08 US claimed
US-20020010337-A1 Stilbene compounds comprising an adamantyl group, compositions and methods thereof BERNARDON JEAN-MICHEL (FR) 2002-01-24 US claimed
US-6214878-B1 SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2001-04-10 US claimed
EP-0850909-B1 Stilbene compounds with adamantyl group, compositions containing the same and uses CT INTERNAT DE (FR) 2001-03-21 EP claimed
EP-0850909-A1 Stilbene compounds with adamantyl group, compositions containing the same and uses CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1998-07-01 EP claimed
US-6992095-B2 Stilbene compounds comprising an adamantyl group, compositions and methods thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US disclosed
US-20020010337-A1 Stilbene compounds comprising an adamantyl group, compositions and methods thereof BERNARDON JEAN-MICHEL (FR) 2002-01-24 US disclosed
US-6214878-B1 SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2001-04-10 US disclosed
EP-0850909-B1 Stilbene compounds with adamantyl group, compositions containing the same and uses CT INTERNAT DE (FR) 2001-03-21 EP disclosed
EP-0850909-A1 Stilbene compounds with adamantyl group, compositions containing the same and uses CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1998-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067971-A1 Stilbene compounds comprising an adamantyl group, compositions and methods thereof SQLE, FDFT1, PIGS RARA 1151/4885IKBKB 485/4885RARB 406/4885
US-20020010337-A1 Stilbene compounds comprising an adamantyl group, compositions and methods thereof SQLE, FDFT1, PIGS RARA 1151/4885IKBKB 485/4885RARB 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.